Bone marrow-derived cell (BMDC) transplantation is increasingly recognized as a valuable strategy in regenerative therapies. However, the data regarding the impact of BMDC transplantation on the severity of diabetes mellitus type 1 (DMT1). This study aimed to determine the effectiveness of adoptive transfer of BMDC isolated from either non-diabetic mice (nBMDC) or diabetic mice (dBMDC) in the treatment of a DMT1 mouse model. Male Swiss albino mice underwent a 16-hour fasting period, followed by administration of streptozotocin (STZ) at a dose of 40 mg/kg body weight for five days to induce DMT1. After 14 days, diabetic mice were divided into four groups. The first group served as a diabetic control and received sodium citrate buffer, while the remaining three groups were treated for two weeks with one of the following: subcutaneous (s.c.) administration of insulin (8 U/kg/day), intravenous (i.v.) inoculation of nBMDCs (1 × 106 cells/mouse/once), or i.v. injections of dBMDC (1 × 106 cells/mouse/once). STZ-induced DMT1 mice treated with either nBMDC or dBMDC exhibited a noticeable increase in the expression of CD4+ T lymphocytes, CD8+ T lymphocytes, and NK lymphocytes, myeloid granulocytic neutrophil (CD11b+/Ly-6G+ cells), monocytic macrophage (CD11b+/Ly-6G− cells), and monocytic CD11b+/Ly-6G− cells. Additionally, there was a marked reduction in the percentages of CD25+ T cells, Foxp3+ cells, regulatory T cells (Tregs), CD25+/Foxp3+ cells, Treg CD25+/Foxp3− cells, Treg CD4+/CD25+ cells, and Treg CD4+/CD25− cells within the myeloid cell population in the spleen. The therapeutic efficacy of BMDC as an anti-diabetic therapy was further supported by a significant reduction in the proportion of early and late apoptosis in splenic leukocytes, accompanied by a slight increase in necrosis in STZ-induced DMT1 mice receiving either nBMDC or dBMDC. In summary, adoptive transfer of BMDCs exerts significant immunomodulatory and anti-apoptotic effects on pancreatic β cells, which are beneficial for pancreatic islets in DMT1 mice. Clinical studies are warranted to evaluate the safety and effectiveness of the adoptive transfer of BMDCs as a potential therapy for autoimmune DMT1.
Nassef et al. (Sat,) studied this question.